Lowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
Author:
- 11 April 2019
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (15) , 1476-1478
Abstract
Some trials fail because the experimental treatment proves to be no different than a control or standard intervention. Others fail because of unacceptable side effects. In this issue of the Journal, an article by Egan et al.1 and a letter to the editor by Henley et al.2 describe a third reason for failure — a treatment worsens the target symptoms. The therapeutic intervention of lowering brain amyloid-beta (Aβ) peptide levels to treat patients with Alzheimer’s disease is based on a conceptual model in which accumulation of Aβ is causally related to cognitive decline. The model is rooted in the inseparability . . .Keywords
This publication has 10 references indexed in Scilit:
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s DiseaseNew England Journal of Medicine, 2019
- Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s DiseaseNew England Journal of Medicine, 2019
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer diseaseNature Reviews Neurology, 2019
- Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled studyAlzheimer's Research & Therapy, 2018
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s DiseaseNew England Journal of Medicine, 2018
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsScience Translational Medicine, 2016
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseaseNature, 2016
- BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current StatusDrugs & Aging, 2013
- Brain β-amyloid load approaches a plateauNeurology, 2013
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive declineNature, 2012